Cardiotoxicity is a significant complication of chemotherapeutic agents in cancer patients.
Cardiovascular incidents including LV dysfunction, heart failure (HF), severe arrhythmias …

Cardiotoxicity due to cancer treatment is of rising concern, for both cardiologists and
oncologists, because it may have a significant impact on cancer patient management and …

Cardiotoxicity is a common complication of many anti-cancer agents and it remains a major
limitation, strongly impacting the quality of life and the overall survival, regardless of the …

Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …

Cardiovascular (CV) diseases and cancer are the leading causes of death in Europe and
the United States. Both diseases have extensive overlap and share common risk factors …

Cardiovascular toxicity is a potential short-or long-term complication of anticancer therapy.
Exposure to chemotherapy medications, primarily the anthracycline class, can lead to …

Cardiovascular toxicity is a potentially serious complication that can result from the use of
various cancer therapies and can impact the short-and long-term prognosis of treated …

Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in
the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic …

Background Cancer patients receiving chemotherapy have an increased risk of
cardiovascular complications. This limits the widespread use of lifesaving therapies, often …

With the improvement in cancer survival, long-term cardiotoxicity has become an area of
increased interest. Various cancer therapies, including chemotherapy and radiation therapy …